[go: up one dir, main page]

CY1123206T1 - Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου - Google Patents

Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου

Info

Publication number
CY1123206T1
CY1123206T1 CY20201100568T CY201100568T CY1123206T1 CY 1123206 T1 CY1123206 T1 CY 1123206T1 CY 20201100568 T CY20201100568 T CY 20201100568T CY 201100568 T CY201100568 T CY 201100568T CY 1123206 T1 CY1123206 T1 CY 1123206T1
Authority
CY
Cyprus
Prior art keywords
myelodysplastic syndrome
telomerase inhibitor
therapeutic management
imetelstat
inhibitor imetelstat
Prior art date
Application number
CY20201100568T
Other languages
English (en)
Inventor
Monic J. STUART
Stephen Kelsey
Original Assignee
Geron Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/841,711 external-priority patent/US9375485B2/en
Application filed by Geron Corporation filed Critical Geron Corporation
Publication of CY1123206T1 publication Critical patent/CY1123206T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

Παρέχονται στο παρόν μέθοδοι για τη μείωση του πολλαπλασιασμού νεοπλασματικών προγονικών κυττάρων και την ανακούφιση από συμπτώματα που συνδέονται με οντότητες που έχουν διαγνωστεί με ή πιστεύεται ότι έχουν μυελοδυσπλαστικό σύνδρομο. Επίσης παρέχονται στο παρόν μέθοδοι για τη χρήση αναστολέων τελομεράσης για τη διατήρηση του αριθμού αιμοπεταλίων σε σχετικά φυσιολογικά εύρη στο αίμα των οντοτήτων που έχουν διαγνωστεί με ή υπάρχει υποψία ότι έχουν μυελοδυσπλαστικό σύνδρομο.
CY20201100568T 2012-12-07 2020-06-23 Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου CY1123206T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261734941P 2012-12-07 2012-12-07
US201361799069P 2013-03-15 2013-03-15
US13/841,711 US9375485B2 (en) 2012-12-07 2013-03-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US201361900347P 2013-11-05 2013-11-05
PCT/US2013/070437 WO2014088785A1 (en) 2012-12-07 2013-11-15 Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP13861008.4A EP2928477B1 (en) 2012-12-07 2013-11-15 Use of the telomerase inhibitor imetelstat for the treatment of myelofibrosis

Publications (1)

Publication Number Publication Date
CY1123206T1 true CY1123206T1 (el) 2021-10-29

Family

ID=50883867

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191101076T CY1122169T1 (el) 2012-12-07 2019-10-14 Χρηση toy αναστολεα τελομερασης imetelstat για τη θεραπεια της μυελοϊνωσης
CY20201100568T CY1123206T1 (el) 2012-12-07 2020-06-23 Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191101076T CY1122169T1 (el) 2012-12-07 2019-10-14 Χρηση toy αναστολεα τελομερασης imetelstat για τη θεραπεια της μυελοϊνωσης

Country Status (35)

Country Link
EP (3) EP3646876B1 (el)
JP (5) JP6433911B2 (el)
KR (3) KR102294819B1 (el)
CN (2) CN111617252A (el)
AP (1) AP2015008504A0 (el)
AU (4) AU2013356533B2 (el)
BR (1) BR112015013260A2 (el)
CA (2) CA3188494A1 (el)
CL (2) CL2015001530A1 (el)
CY (2) CY1122169T1 (el)
DK (3) DK3646876T3 (el)
EA (1) EA032973B1 (el)
ES (3) ES2982897T3 (el)
FI (1) FI3646876T3 (el)
HK (2) HK1210940A1 (el)
HR (3) HRP20240624T1 (el)
HU (3) HUE045098T2 (el)
IL (3) IL317233A (el)
LT (3) LT3456333T (el)
MA (2) MA38193B1 (el)
ME (1) ME03538B (el)
MX (3) MX372753B (el)
MY (1) MY180634A (el)
NZ (1) NZ708920A (el)
PH (2) PH12019501008A1 (el)
PL (3) PL3456333T3 (el)
PT (3) PT3456333T (el)
RS (2) RS60401B1 (el)
SG (3) SG11201504383TA (el)
SI (3) SI3646876T1 (el)
SM (2) SMT202000328T1 (el)
TN (1) TN2015000249A1 (el)
UA (3) UA117116C2 (el)
WO (1) WO2014088785A1 (el)
ZA (2) ZA201504124B (el)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778711B1 (en) 2004-07-02 2017-08-16 Geron Corporation Synthesis of protected 3'-amino nucleoside monomers
CR20190343A (es) 2013-08-07 2019-10-02 Incyte Corp FORMAS DE DOSIFICACIÓN DE LIBERACIÓN PROLONGADA PARA UN INHIBIDOR DE JAK 1 (Divisional de Exp: 2016-0102)
DK3065828T3 (en) * 2013-11-06 2019-04-15 Mayo Found Medical Education & Res METHODS AND MATERIALS FOR TREATING HEMATOLOGICAL MALIGNITIES
CN107429247B (zh) 2015-04-23 2021-08-13 美国杰龙生物医药公司 使用多价阳离子盐组合物制备多核苷酸的方法
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
JP7316261B2 (ja) 2017-07-28 2023-07-27 ジェロン・コーポレーション 骨髄異形成症候群の治療方法
JP2021523220A (ja) * 2018-04-30 2021-09-02 カルトス セラピューティクス，インコーポレイテッド がんの治療方法
CN112770783B (zh) * 2018-07-31 2025-02-25 美国杰龙生物医药公司 鉴定可能从端粒酶抑制剂治疗中受益的患者的方法
AU2019389005B2 (en) 2018-11-29 2024-06-20 Geron Corporation Methods of treating myelodysplastic syndrome
MX2022005354A (es) * 2019-11-04 2022-10-21 Geron Corp Uso de un inhibidor de la cinasa janus y un inhibidor de la telomerasa para el tratamiento de neoplasias mieloproliferativas.
JP2021157248A (ja) * 2020-03-25 2021-10-07 パイオニア株式会社 状況出力装置
WO2024259369A1 (en) * 2023-06-14 2024-12-19 Rarecells Inc. Compositions targeting giant cells in blood disorders

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
CA2274586A1 (en) 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
CA2515000A1 (en) * 2003-01-31 2004-08-19 Jessie L.-S. Au Methods and compositions for using suramin, pentosan polysulfate, telomerase antisense, and telomerase inhibitors
CN1244592C (zh) * 2003-07-11 2006-03-08 暨南大学 抑制白血病细胞端粒酶活性的反义核酸及其应用
PL1667522T3 (pl) 2003-09-09 2018-06-29 Geron Corporation Zmodyfikowane oligonukleotydy do hamowania telomerazy
US20050282893A1 (en) * 2004-01-30 2005-12-22 Au Jessie L Methods and compositions for using suramin, pentosan, polysulfate, telomerase antisense and telomerase inhibitors
EP1778711B1 (en) 2004-07-02 2017-08-16 Geron Corporation Synthesis of protected 3'-amino nucleoside monomers
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US20060166221A1 (en) 2005-01-21 2006-07-27 Bahou Wadie F Methods of diagnosing essential thrombocythemia
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006113426A2 (en) * 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
US20070224598A1 (en) 2006-03-15 2007-09-27 The Methodist Hospital Research Institute System and method for detection of mutations in JAK2 polynucleotides
US20080021013A1 (en) 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
PL2898887T3 (pl) 2006-10-30 2019-05-31 Geron Corp Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu
CN101220044B (zh) * 2008-01-21 2010-06-02 中国药科大学 端粒酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
EP3456333B8 (en) 2020-05-13
EP2928477A4 (en) 2016-09-21
MX2020003276A (es) 2020-07-20
AP2015008504A0 (en) 2015-06-30
KR20150091130A (ko) 2015-08-07
MA38193B1 (fr) 2018-12-31
PH12015501282A1 (en) 2015-08-24
AU2024203138A1 (en) 2024-07-25
AU2013356533A1 (en) 2014-06-12
PH12019501008A1 (en) 2022-11-14
AU2020267142B2 (en) 2024-05-16
WO2014088785A8 (en) 2015-07-16
DK3646876T3 (da) 2024-05-06
ZA202108991B (en) 2023-05-31
JP7288098B2 (ja) 2023-06-06
RS60401B1 (sr) 2020-07-31
UA126015C2 (uk) 2022-08-03
CN111617252A (zh) 2020-09-04
EP3456333A1 (en) 2019-03-20
JP2022179684A (ja) 2022-12-02
PL3646876T3 (pl) 2024-07-22
JP2022050537A (ja) 2022-03-30
ES2982897T3 (es) 2024-10-18
MX2015007169A (es) 2016-03-31
HUE049858T2 (hu) 2020-11-30
CN104936602A (zh) 2015-09-23
HRP20191784T1 (hr) 2019-12-27
UA117116C2 (uk) 2018-06-25
CA3188494A1 (en) 2014-06-12
EP3646876B1 (en) 2024-02-14
CL2015001530A1 (es) 2016-03-28
NZ748134A (en) 2020-10-30
CA2892907C (en) 2023-03-21
HRP20200993T1 (hr) 2020-11-27
HUE045098T2 (hu) 2019-12-30
CL2017002156A1 (es) 2018-05-04
TN2015000249A1 (en) 2016-10-03
IL280144A (en) 2021-03-01
CN104936602B (zh) 2020-07-17
MX372753B (es) 2025-03-05
FI3646876T3 (fi) 2024-05-14
MA38193A1 (fr) 2017-12-29
PT3646876T (pt) 2024-05-15
RS59363B1 (sr) 2019-11-29
AU2013356533B2 (en) 2018-09-27
BR112015013260A2 (pt) 2018-02-06
JP2020041001A (ja) 2020-03-19
CY1122169T1 (el) 2020-11-25
JP2018035196A (ja) 2018-03-08
IL317233A (en) 2025-01-01
SMT201900567T1 (it) 2019-11-13
ZA201504124B (en) 2017-05-31
EA032973B1 (ru) 2019-08-30
NZ708920A (en) 2020-08-28
MX2022015437A (es) 2023-01-11
MY180634A (en) 2020-12-03
SI3456333T1 (sl) 2020-10-30
LT3456333T (lt) 2020-06-25
LT3646876T (lt) 2024-05-10
KR102294819B1 (ko) 2021-09-01
IL239266A0 (en) 2015-07-30
CA2892907A1 (en) 2014-06-12
HK1212226A1 (en) 2016-06-10
JP2016504307A (ja) 2016-02-12
AU2018282364A1 (en) 2019-05-23
SI3646876T1 (sl) 2024-07-31
IL280144B1 (en) 2025-01-01
JP6998191B2 (ja) 2022-02-04
PT3456333T (pt) 2020-06-01
DK2928477T3 (da) 2019-10-07
EP3646876A1 (en) 2020-05-06
SMT202000328T1 (it) 2020-07-08
UA128370C2 (uk) 2024-06-26
ES2789176T3 (es) 2020-10-26
AU2020267142A1 (en) 2020-12-03
KR102662590B1 (ko) 2024-05-03
HK1210940A1 (en) 2016-05-13
HUE066402T2 (hu) 2024-07-28
JP6433911B2 (ja) 2018-12-05
PL2928477T3 (pl) 2020-03-31
MA45504B1 (fr) 2021-10-29
SI2928477T1 (sl) 2019-11-29
IL239266B (en) 2019-11-28
MA45504A1 (fr) 2020-05-29
WO2014088785A1 (en) 2014-06-12
HRP20240624T1 (hr) 2024-08-02
KR20230028590A (ko) 2023-02-28
ME03538B (me) 2020-07-20
EA201590878A1 (ru) 2016-04-29
LT2928477T (lt) 2019-10-10
EP2928477B1 (en) 2019-07-24
EP3456333B1 (en) 2020-04-01
SG10202103341SA (en) 2021-05-28
ES2744790T3 (es) 2020-02-26
KR20210107906A (ko) 2021-09-01
PT2928477T (pt) 2019-10-25
SG11201504383TA (en) 2015-07-30
DK3456333T3 (da) 2020-05-18
PL3456333T3 (pl) 2020-09-21
PH12015501282B1 (en) 2015-08-24
EP2928477A1 (en) 2015-10-14
AU2020267142C1 (en) 2024-08-08
SG10201802926XA (en) 2018-05-30

Similar Documents

Publication Publication Date Title
CY1123206T1 (el) Χρηση του αναστολεα τελομερασης ιμετελστατη για τη θεραπευτικη αγωγη του μυελοδυσπλαστικου συνδρομου
CY1123647T1 (el) Διαμορφωση της ανοσιας ογκων
CY1120646T1 (el) Προγονικα κυτταρα μεσοδερμικης προελευσης
HK1254962A1 (zh) 具有改進特異性的修飾的t淋巴細胞
DOP2015000108A (es) Compuestos de pirrolopirimidina como inhibidores de quinasas
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
CL2018003282A1 (es) Métodos y composiciones para el tratamiento de cánceres resistentes a los inhibidores de la vía no erk mapk
CO7350624A2 (es) Inhibidores de la tirosina-quinasa de bruton
HUE055072T2 (hu) B-Raf gátlót és második gátlószert tartalmazó kombinációs terápia
CR20150507A (es) Inhibidores de histona desmetilasas
CY1124140T1 (el) Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης
TR201811764T4 (tr) Kinaz inhibitörleri olarak aminoheteroaril benzamidleri.
HUE042801T2 (hu) Kombinációs terápia mitózisgátlóval
CO7400876A2 (es) Etanercept correctamente plegado de alta pureza y excelente rendimiento
BR112013027716A2 (pt) gavetas rápidas com rolos e rampa
DK3284463T3 (da) Nitroxyldonorer med forbedret terapeutisk indeks
LT3049117T (lt) Vaistų įvedimas ultragarso pagalba
EP2986710A4 (en) AGE-MODIFIED CELLS AND METHOD FOR PRODUCING AGED-MODIFIED CELLS
CR20140481A (es) Compuestos triazolo como inhibidores de pde10
DK2984184T3 (da) Anvendelse af dnq eller dnq-87 i kombination med en parp1-inhibitor til behandlingen af cancer
UY4240Q (es) Silla con respaldo en forma oval
BR112015024771A2 (pt) cateter
UY4228Q (es) Taburete mecedor guardabultos para niños
FR3003871B1 (fr) Proteine kinase aurora a mutee sensible a un inhibiteur
UA79807U (uk) Конструкційний дерев'яний брус